Leier C B, Magorien R D, Desch C E, Thompson M J, Unverferth D V
Circulation. 1981 Jan;63(1):102-9. doi: 10.1161/01.cir.63.1.102.
Central and regional hemodynamic studies were performed before and after the oral administration of 75 mg of hydralazine and/or 20 mg of isosorbide dinitrate in 15 patients with low-output congestive heart failure. Hydralazine increased mean cardiac output 17-25%, mean renal blood flow 19%, and limb blood flow 17% (all p < 0.05). Mean hepatic blood flow did not change significantly with hydralazine. Except for a small increase in cardiac output (6%, p < 0.05) at 30 minutes, isosorbide dinitrate did not significantly alter central, renal, hepatic or limb blood flow. Combining isosorbide dinitrate and hydralazine effected similar increases in cardiac output (17-24%, p < 0.05), renal (17%, p < 0.05) and limb (20%, p < 0.05) blood flow as those elicited by hydralazine alone. The combination did not significantly alter mean hepatic blood flow. Hydralazine, alone or combined with isosorbide dinitrate, increases renal and limb blood flow in congestive heart failure in proportion to the augmented cardiac output; isosorbide dinitrate alone does not alter blood flow to these regions. Neither drug (or combination) changes hepatic blood flow in this clinical setting.
对15例低输出量充血性心力衰竭患者在口服75毫克肼屈嗪和/或20毫克硝酸异山梨酯之前和之后进行了中心和区域血流动力学研究。肼屈嗪使平均心输出量增加17 - 25%，平均肾血流量增加19%，肢体血流量增加17%（均p < 0.05）。肼屈嗪使平均肝血流量无显著变化。除在30分钟时心输出量有小幅增加（6%，p < 0.05）外，硝酸异山梨酯未显著改变中心、肾、肝或肢体血流量。联合使用硝酸异山梨酯和肼屈嗪使心输出量（17 - 24%，p < 0.05）、肾血流量（17%，p < 0.05）和肢体血流量（20%，p < 0.05）的增加幅度与单独使用肼屈嗪时相似。联合用药未显著改变平均肝血流量。单独使用肼屈嗪或与硝酸异山梨酯联合使用时，充血性心力衰竭患者的肾血流量和肢体血流量会随着心输出量的增加而成比例增加；单独使用硝酸异山梨酯不会改变这些区域的血流量。在这种临床情况下，两种药物（或联合用药）均不会改变肝血流量。
